Skip to main content

Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Table 1 Characteristics of the included trials

From: What is the effect of perioperative intravenous iron therapy in patients undergoing non-elective surgery? A systematic review with meta-analysis and trial sequential analysis

Study Serrano-Trenas et al. (2011) Mudge et al. (2012) Bernabeu-Wittel et al. (2016)
Patient population Age > 65 undergoing hip fracture surgery Adults undergoing living-donor or deceased-donor kidney transplantation Age > 65 requiring hip fracture surgery with Hb levels between 90 and 120 g/L
Country Spain Australia Spain
No. of centres 1 1 13
No. of patients randomised 200 102 303
Intervention 600 mg of IV iron sucrose (Venofer) in three doses of 200 mg at 48-h intervals
- First dose always administered before surgery
500 mg of IV iron polymatose on the 4th postoperative day 3 arms
• EPOFE—subcutaneous single dose of EPO 40,000 IU and 1000 mg of IV ferric carboxymaltose
• FE—1000 mg of IV ferric carboxymaltose and subcutaneous placebo (saline)
Comparator Usual care 210 mg of oral slow release ferrous sulfate daily until primary endpoint was reached Subcutaneous single dose placebo and IV placebo (saline)
Primary outcome(s) • Number and rate of patients transfused postoperatively in each arm • Resolution of anaemia defined as haemoglobin concentration more than or equal to 11 g/dL for both men and women • Percentage of patients who received an RBC transfusion during hospitalisation and after 60 days from hospital discharge
Secondary outcome(s) • Mean number of RBCs per patient
• Changes in haematinic variables (admission, 24 h and 7 days postoperatively)
• Hospital length of stay
• Infection
• 30-day mortality
• Side-effects
• Gastrointestinal symptoms
• Infusion reactions
• Acute rejection episodes
• Infectious episodes
• Blood transfusion
• ESA administration
• Number of RBC transfusions per patient
• Hb levels 24 and 72 h after surgery, at discharge, and after 60 days
• All-cause mortality
• Adverse events
• HRQoL
• Medical complications—acute coronary disease, stroke, heart failure, VTE, COPD exacerbation, deterioration in renal function, infection, delirium, pressure ulcers
  1. Hb haemoglobin, ESA erythropoiesis-stimulating agents, EPO erythropoietin, HRQoL health-related quality of life, RBC red blood cell